RESTEX

This brand name is authorized in Austria, Germany

Active ingredients

The drug RESTEX contains a combination of these active pharmaceutical ingredients (APIs):

1 Levodopa
UNII 46627O600J - LEVODOPA

According to the current understanding, the symptoms of Parkinson’s disease are related to depletion of dopamine in the corpus striatum. Dopamine does not cross the blood-brain barrier. Levodopa, the precursor of dopamine, crosses the blood brain barrier and relieves the symptoms of the disease.

Read about Levodopa
2 Benserazide
UNII B66E5RK36Q - BENSERAZIDE HYDROCHLORIDE

Benserazide (also called Serazide or Ro 4-4602) is a peripherally acting aromatic L-amino acid decarboxylase or DOPA decarboxylase inhibitor, which is unable to cross the blood–brain barrier.

Read about Benserazide

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
N04BA02 Levodopa and decarboxylase inhibitor N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BA Dopa and dopa derivatives
Discover more medicines within N04BA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: DE Bundesinstitut fĂźr Arzneimittel und Medizinprodukte Identifier(s): 00576148, 00576160, 05515513, 05515542, 15317553

Š All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈